Stem Cells Infusion Reduced HF Risk in AMI
Intracoronary infusion of Wharton’s jelly–derived mesenchymal stem cells after acute myocardial infarction (AMI) significantly reduced the risk of developing heart failure (HF) and related adverse cardiovascular events, suggesting its potential as a valuable adjunctive therapy. In a Iranian phase 3 randomized clinical trial involving 420 patients with a first ST-segment […]